IL-33 is a nuclear cytokine from the IL-1 family with dual functions in homeostasis and inflammation. In quiescent endothelia, uncleaved IL-33 acts as a chr9-associated nuclear factor with transcriptional repressor properties, sequestering NF-κB/RELA to lower target expression 1. Upon angiogenic or pro-inflammatory activation, this nuclear form is rapidly lost 2. IL-33 functions as an alarmin—passively released during cell necrosis or tissue damage rather than through active secretion 34. Once released, IL-33 engages ST2 receptor on diverse immune cells including mast cells, group 2 innate lymphoid cells (ILC2s), regulatory T cells (Tregs), and macrophages, acting as a crucial immune modulator in type-2, type-1, and regulatory responses 3. Notably, IL-33 mediates immunosuppression through multiple pathways: in cancer contexts, it enhances cancer stem cell formation via CD44-IL-33 signaling 5 and promotes Treg-mediated tumor immunosuppression through macrophage-derived IL-33 67. In chr9 atrophic gastritis, IL-33 accelerates disease through AMPK-ULK1-mediated autophagy 8. Clinically, IL-33/ST2 signaling variants represent highly replicated susceptibility loci for asthma 3, and blocking ST2 or deleting IL-33 enhances cancer immunotherapy responses 6.